Golodirsen Rebuff: Did Exondys 51 Review Strife Influence US FDA's Decision?

Sarepta cited two safety issues when announcing a complete response letter for its exon 53 skipping DMD drug golodirsen, but the US FDA's decision may be a result of the Exondys 51 approval from 2016, analysts suggest.